Compass Therapeutics Statistics
Share Statistics
Compass Therapeutics has 137.59M shares outstanding. The number of shares has increased by 7.92% in one year.
| Shares Outstanding | 137.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 84.48M |
| Failed to Deliver (FTD) Shares | 17 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 1.79M, so 1.3% of the outstanding shares have been sold short.
| Short Interest | 1.79M |
| Short % of Shares Out | 1.3% |
| Short % of Float | 2.1% |
| Short Ratio (days to cover) | 3.71 |
Valuation Ratios
The PE ratio is -4.66 and the forward PE ratio is -3.51.
| PE Ratio | -4.66 |
| Forward PE | -3.51 |
| PS Ratio | 0 |
| Forward PS | 37.6 |
| PB Ratio | 1.33 |
| P/FCF Ratio | -4.88 |
| PEG Ratio | n/a |
Enterprise Valuation
Compass Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 19.73, with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.73 |
| Quick Ratio | 19.73 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.15 |
| Cash Flow / Debt | -23.44 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.29% and return on capital (ROIC) is -33.51%.
| Return on Equity (ROE) | -0.29% |
| Return on Assets (ROA) | -0.27% |
| Return on Capital (ROIC) | -33.51% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.33M |
| Employee Count | 32 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -8.18% in the last 52 weeks. The beta is 0.75, so Compass Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.75 |
| 52-Week Price Change | -8.18% |
| 50-Day Moving Average | 1.69 |
| 200-Day Moving Average | 1.51 |
| Relative Strength Index (RSI) | 42.32 |
| Average Volume (20 Days) | 504.73K |
Income Statement
In the last 12 months, Compass Therapeutics had revenue of $0 and earned -$42.49M in profits. Earnings per share was $-0.33.
| Revenue | 0 |
| Gross Profit | -1.89M |
| Operating Income | -50.36M |
| Net Income | -42.49M |
| EBITDA | -48.47M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.33 |
Balance Sheet
The company has $24.23M in cash and $1.73M in debt, giving a net cash position of $22.50M.
| Cash & Cash Equivalents | 24.23M |
| Total Debt | 1.73M |
| Net Cash | 22.50M |
| Retained Earnings | -315.31M |
| Total Assets | 149.15M |
| Working Capital | 136.71M |
Cash Flow
In the last 12 months, operating cash flow was -$40.62M and capital expenditures -$30.00K, giving a free cash flow of -$40.65M.
| Operating Cash Flow | -40.62M |
| Capital Expenditures | -30.00K |
| Free Cash Flow | -40.65M |
| FCF Per Share | -0.32 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
CMPX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -22.6% |
| FCF Yield | -20.3% |
Analyst Forecast
The average price target for CMPX is $8, which is 447.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 447.9% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 8.21 |
| Piotroski F-Score | 3 |